MedTrace Logo

The Epigenetic Modification in OPRM1 on Postoperative Analgesia and Side Effect Induced by Sufentanil

NCT03135795 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2017-05-01

No results posted yet for this study

Summary

To explore the epigenetic mechanism of postoperative analgesia and side effect induced by μ-opioid Receptor Agonists presented with sufentanil among general population.

Conditions

  • Epigenetics

Interventions

DRUG

Sufentanil

Patients received intravenous sufentanil 0.5μg/kg for induction,and received PCA after surgery with sufentanil 1ug/ml using a controlled infusion pump, which was programmed to use a loading dose of 2ml, background infusion at 2m/h, PCA dose of 1ml, lockout time of 10min, and maximal dose of 12ml within 1 hour period.

DRUG

dexmedetomidine

Patients received intravenous dexmedetomidine 1μg/Kg for induction.

DRUG

propofol

Patients received intravenous propofol 2mg/Kg for induction, and received intavenous pump of propofol (0.3-0.6mg/kg/h) for maintenance.

DRUG

Rocuronium

Patients received intravenous rocuronium 0.6mg/Kg for induction.

DRUG

sevoflurane

Patients received inhalation of sevoflurane (1-2%) for maintenance.

DRUG

remifentanil

Patients received intavenous pump of remifentanil (0.1-0.2ug/kg/min) for maintenance.

DRUG

Parecoxib

Parecoxib 40mg was given single intravenously before incision.

Sponsors & Collaborators

  • Huazhong University of Science and Technology

    lead OTHER

Principal Investigators

  • Xu Hui · Department of Anaesthesiology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-06
Primary Completion
2017-05-31
Completion
2017-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03135795 on ClinicalTrials.gov